COMBINED CHELATION THERAPY WITH DEFERASIROX AND DEFEROXAMINE IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA

被引：0
|
作者：
Ladis, V. [1 ]
Delaporta, P. [1 ]
Kyriakopoulou, D. [1 ]
Kattamis, A. [1 ]
机构：
[1] Univ Athens, Athens, Greece
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1818
引用
收藏
页码：703 / 703
页数：1
相关论文
共 50 条
  • [1] Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia
    Lal, Ashutosh
    Sweeters, Nancy
    Ng, Vivian
    Foote, Drucilla
    Evans, Patricia
    Neumayr, Lynne
    Kurio, Gregory
    Harmatz, Paul
    Porter, John B.
    Vichinsky, Elliott
    BLOOD, 2010, 116 (21) : 1732 - 1733
  • [2] Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.
    Lal, Ashutosh
    Sweeters, Nancy
    Herz, Matt
    Foote, Dru
    Neumayr, Lynne
    Kurio, Greg
    Harmatz, Paul R.
    Vichinsky, Elliott P.
    BLOOD, 2009, 114 (22) : 798 - 798
  • [3] Combined chelation therapy with deferasirox and deferoxamine in thalassemia
    Lal, Ashutosh
    Porter, John
    Sweeters, Nancy
    Ng, Vivian
    Evans, Patricia
    Neumayr, Lynne
    Kurio, Gregory
    Harmatz, Paul
    Vichinsky, Elliott
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 50 (02) : 99 - 104
  • [4] Cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients
    Delea, T
    Sofrygin, O
    Thomas, S
    Baladi, JF
    Phatak, P
    Coates, TD
    VALUE IN HEALTH, 2006, 9 (03) : A143 - A143
  • [5] Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia
    Haghpanah, Sezaneh
    Zarei, Tahereh
    Zahedi, Zohreh
    Karimi, Mehran
    HEMATOLOGY, 2014, 19 (04) : 187 - 191
  • [6] Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients
    Keshtkaran, Ali
    Javanbakht, Mehdi
    Salavati, Sedigheh
    Mashayekhi, Atefeh
    Karimi, Mehran
    Nuri, Bijan
    TRANSFUSION, 2013, 53 (08) : 1722 - 1729
  • [7] DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA RECEIVING LOW TRANSFUSION INTENSITIES
    Cappellini, M. D.
    Taher, A. T.
    Kattamis, A.
    Piga, A.
    Al-Jefri, A.
    Rose, C.
    Vorog, A.
    Quebe-Fehling, E.
    Porter, J. B.
    HAEMATOLOGICA, 2014, 99 : 443 - 443
  • [8] Deferasirox: optimal chelation in transfusion-dependent anaemia
    Perrotta, S.
    Casale, M.
    PEDIATRIC REPORTS, 2012, 4 : 29 - 33
  • [9] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Michael D. Diamantidis
    Nikolaos Neokleous
    Aleka Agapidou
    Evaggelia Vetsiou
    Achilles Manafas
    Paraskevi Fotiou
    Efthymia Vlachaki
    International Journal of Hematology, 2016, 103 : 537 - 544
  • [10] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis, Michael D.
    Neokleous, Nikolaos
    Agapidou, Aleka
    Vetsiou, Evaggelia
    Manafas, Achilles
    Fotiou, Paraskevi
    Vlachaki, Efthymia
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (05) : 537 - 544
12345